The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

Gaxiola López shaped the field of interventional cardiology, with colleagues saying he’ll be remembered as a “visionary.” ...

Echocardiograms reveal a rapid rise in LV hypertrophy from ages 17 to 24 years, bolstering the case for primordial prevention.

Gaxiola López shaped the field of interventional cardiology, with colleagues saying he’ll be remembered as a “visionary.” ...

By improving BP control and treatment adherence, use of fixed-dose combination therapies is expected to drive down CV events ...

Office and ambulatory BP improved, with minimal side effects, although some say edema needs to be watched carefully.

Angina patients with no obstructive CAD had no worse outcomes over 15 years, perhaps because they got the care they needed.

The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.

The US Food and Drug Administration has approved the use of lerodalcibep (Lerochol) to reduce LDL cholesterol alongside ...

Panelists considered the technology relatively safe but weren’t swayed by the “statistical gymnastics” needed to find a ...

The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.

Understanding the athlete heart in light of normal aging and CV risk requires a nuanced look at imaging findings, the paper ...